Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib

Next Previous
Trial Profile

Jaktinib in Intermediate-risk and High-risk Myelofibrosis and Previously Treated With Ruxolitinib

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 Oct 2023 Results assessing safety and efficacy of jaktinib, a novel JAK inhibitor in patients with ruxolitinib-intolerant MF published in the American Journal of Hematology
  • 06 Jun 2023 Results(n=45) assessing safety and efficacy of Jaktinib in patients with myelofibrosis who were intolerant to ruxolitinib presented at the 59th Annual Meeting of the American Society of Clinical Oncology
  • 18 Apr 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top